Nexalin Technology (NXL) Expected to Post Quarterly Earnings on Friday

Nexalin Technology (NASDAQ:NXL) is projected to issue its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($2.91) per share and revenue of $0.07 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 4:00 PM ET.

Nexalin Technology (NASDAQ:NXL) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($3.00) by $2.89. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.09 million. Nexalin Technology had a negative return on equity of 278.24% and a negative net margin of 4,141.94%. On average, analysts expect Nexalin Technology to post ($11.42) EPS for the current fiscal year and ($7.55) EPS for the next fiscal year.

Nexalin Technology Stock Down 2.0%

NXL opened at $1.47 on Wednesday. The stock has a 50-day moving average price of $3.62 and a 200-day moving average price of $10.35. Nexalin Technology has a 1 year low of $1.31 and a 1 year high of $40.20.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NXL. Zacks Research upgraded shares of Nexalin Technology to a “hold” rating in a research note on Thursday, October 1st. Weiss Ratings downgraded shares of Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

Nexalin Technology Company Profile

Nexalin Technology, Inc. (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems.